Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

The annual UNIVANTS of Healthcare Excellence Award was given to credit the working partnership between Roche Diagnostics, Oxford University Hospitals NHS Foundation Trust and Oxford Academic Health Science Network. Their joint expertise resulted in a new test which predicts with much greater accuracy, whether a pregnant woman will develop Pre-eclampsia (PE) within the following seven days.

Pre- eclampsia is a hypertensive disorder of pregnancy, affecting 4-8% of women globally, causing major maternal and fetal morbidity. Roughly half of patients who are admitted to the hospital at risk of PE don’t end up suffering from the condition. Significant resources are used trying to identify PE mothers by measuring blood pressure and proteinuria. This is sub-optimal because these clinical signs have poor diagnostic accuracy, which means clinicians rely on clinical instinct.

“If you don’t have a firm diagnosis, you either incorrectly send someone with Pre-eclampsia home or incorrectly admit someone who doesn’t have Pre-eclampsia,” Vatish said. “Those are both bad outcomes for the professionals involved in their care.” 

Dr Manu Vatish, Dr Sofia Cerdeira and Dr Tim James (Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust) worked extensively around the potential use of laboratory tests that could offer clinicians reassurance of their PE diagnosis while avoiding hospitalization of patients who won’t develop the condition. They found significant opportunity in two angiogenic biomarkers: Placental Growth Factor (PlGF), and its receptor, Soluble Flt-1. These biomarkers showed a very powerful negative predictive value, meaning they were a reliable indicator of patients who were not likely to develop PE.

The test was developed by Roche Diagnostics and a clinical trial was run at the John Radcliffe Hospital (Oxford University Hospitals NHS Foundation Trust). Following improved patient outcomes, the Oxford Academic Health Science Network launched the test to other maternity units across the UK. It has been well-received by patients, who are often unnecessarily frightened when PE is explained to them during prenatal visits. Hospitalization can be a frustrating experience for patients who ultimately have their baby without issue.

This high profile award attracted 300 applications from 97 countries. It is a fantastic acknowledgment of how shared expertise across disciplines, including the core laboratory, can reshape care pathways and ultimately achieve better outcomes for patients, clinicians, payers and entire health systems. 


Latest news

New appointment at Bill & Melinda Gates Foundation

Congratulations to Manu Vatish, Professor of Obstetrics & Consultant Obstetrician who has been appointed as the new Deputy Director for Maternal and Child Health Discovery at the Bill & Melinda Gates Foundation.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

What is the impact of heavy menstrual bleeding on female health and well-being?

Many of us have no idea whether or not our period is “normal”. It’s no wonder, since not only is everyone different, but the stigma still keeps many of us from asking questions or discussing what we go through every month with friends and family. Principal Investigator Prof Suzannah Williams and DPhil student Tomi Adeniran explore what heavy periods can mean in their article published in The Conversation.

Maternal fat metabolism in pregnancy and fetal abdominal growth influence child weight

A new study, led by researchers at the Nuffield Department of Women's & Reproductive Health, University of Oxford, in collaboration with the University of California, Berkeley, USA, published in The Lancet Diabetes & Endocrinology identifies, as early as the 5th month of pregnancy, patterns of fetal abdominal growth associated with maternal lipid metabolites that track newborn growth, adiposity and development into childhood.

Similar stories

New Professor of Obstetrics Title

Enormous well done to our new Professor Sally Collins - she was conferred the title of Professor of Obstetrics by the University's Medical Sciences Division Board.

INTERCOVID Study cited in the New Yorker

Fantastic news for our team who have been working on the INTERCOVID Study, which launched in April 2020. This week on 12th August 2022, the research findings cited in the New Yorker! This work was a combined effort from 43 institutions in 18 countries and involved more than two thousand pregnant women.

Women's Health Strategy for England Launched

The government has published the first ever Women's Health Strategy for England to tackle the gender health gap. Menopause, Endometriosis, Contraception and Fertility treatment are highlighted as some of the top issues women have asked for action on. The Nuffield Department of Women's & Reproductive Health welcome and fully support this bold and exciting strategy to help improve the health of millions of women in England.

Pregnancy is more likely with urine tests and timed intercourse

Dr Tatjana Gibbons leads study that suggests a woman's chance of conceiving is improved by using urine tests to detect the optimum time for intercourse, but further research is still needed to assess whether timed intercourse via any ovulation detection method creates a difference in live births and pregnancy rates.

Dawes-Redman Education awarded funds from Huntleigh Healthcare

The Dawes-Redman Education programme which offers virtual CTG Analysis training sessions to Obstetric consultants, antenatal and student midwifes has received generous funds from Huntleigh Healthcare for the next 3 years.

First UK pilot study of newborn screening for spinal muscular atrophy (SMA) launched in Oxford

Spinal muscular atrophy (SMA) is a rare, but treatable, genetic disease affecting approximately 1 in 10,000 births, and it typically presents in infancy and early childhood.